Abstract

BackgroundRandomised trials that have tested targeted therapies (targeted synthetic disease modifying antirheumatic drugs, tsDMARDs and biological disease modifying antirheumatic drugs, bDMARDs) for rheumatoid arthritis (RA) vary in several of their...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study.
Daniel E Furst ... Shervin Assassi
PloS one | VOL. 10
Daniel E Furst, et. al.Daniel E Furst ... Shervin Assassi
11 Sep 2015
AB0441 Abatacept in Rheumatoid Arthritis (RA) Patients: Real-Life Experience in A Subregional Centre in Uk
S Roskell ... T Sheeran
Annals of the Rheumatic Diseases | VOL. 73
S Roskell, et. al.S Roskell ... T Sheeran
01 Jun 2014
AB1084 Treatment Patterns and Retention in an Inception Cohort of 309 RA Patients
F Alasti ... J.S Smolen
Annals of the Rheumatic Diseases | VOL. 73
F Alasti, et. al.F Alasti ... J.S Smolen
01 Jun 2014
Conventional Synthetic Dmards in Psoriatic Arthritis: Changing Practice in Biologic Era; Real-Life Results from HURBIO-PsA Registry
Emre Bilgin ... Umut Kalyoncu
Acta Medica | VOL. -
Emre Bilgin, et. al.Emre Bilgin ... Umut Kalyoncu
16 Nov 2021
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers